MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MIMEDX (Nasdaq: MDXG) reported third-quarter 2026 net sales of $62.283 million, as Wound sales declines outweighed Surgical franchise growth. Sales fell 45% year over year; Surgical sales rose 9%, while Wound sales fell 71%. Net loss was $8.683 million, versus net income of $16.748 million a year earlier. Gross margin was 80%, versus 84% a year earlier and 69% last quarter.
MIMEDX expects 2026 sales of $250–$260 million and sequentially higher fourth-quarter adjusted EBITDA, an adjusted earnings measure. It repaid its remaining $17 million term loan and ended September debt-free with $120.791 million in cash. A patent license provides $25 million in five annual installments, with the first received. The proposed Sanara acquisition awaits antitrust clearance. A federal court vacated FDA classification determinations for AXIOFILL and returned both matters to the agency for reconsideration.
MIMEDX (MDXG) has entered into a patent license agreement with a wound care competitor providing for payments totaling $25 million.
The agreement grants the counterparty a non-exclusive license to the covered patents. Payments are structured as five equal installments of $5 million. The first installment has been received, and the four remaining installments will be paid annually on the anniversary of the signing date. MIMEDX said the agreement will provide recurring cash over the next several years.
MIMEDX (MDXG) will report its third-quarter operating and financial results after market close on October 28, 2026. The results cover the quarter ended September 30, 2026. Senior management will host a webcast and conference call at 4:30 p.m. Eastern Time that day. A webcast replay will be available on the company’s website for approximately 30 days after the event.
MIMEDX (MDXG) announced on September 23, 2026, that a federal court vacated two FDA determinations concerning AXIOFILL.
The U.S. District Court for the Northern District of Georgia set aside the finding that AXIOFILL does not qualify as a Section 361 human cell or tissue product because it is more than minimally manipulated. It also vacated the FDA’s determination that AXIOFILL should be classified as a biological product rather than a medical device. Both matters return to the FDA for reconsideration. The court held that the manipulation analysis must consider tissue characteristics relevant to reconstruction, repair or replacement in the recipient.
MiMedx Group (MDXG)/b) will participate in two investor conferences in New York, NY in September 2026.Senior management is scheduled for 1:1 sessions at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, and at the Lake Street BIG10 Best Ideas Growth Conference on Thursday, September 10, 2026. Investors who wish to meet with management at these events may contact their Cantor or Lake Street representative.
MIMEDX (Nasdaq: MDXG) reported second quarter 2026 net sales of $64 million, down 35% from $98.6 million a year earlier. Surgical product revenue grew 15% year over year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes effective January 1.
Gross profit was $44.4 million with a 69% margin versus 81% a year ago. SG&A declined to $59.8 million, but higher bad debt expense contributed to a net loss of $14.8 million, compared with $9.6 million of net income in the prior-year quarter. Cash and cash equivalents were $135.8 million at June 30, 2026.
MIMEDX also agreed to acquire Sanara MedTech (Nasdaq: SMTI) for $35 per share in cash and stock, implying about $350 million enterprise value. Each Sanara share will receive $33.00 in cash plus 0.4735 MIMEDX shares, a 46% premium to Sanara’s 30-day VWAP. MIMEDX plans to fund the cash portion with cash on hand and a new $300 million term loan from Hayfin, and reaffirmed 2026 net sales guidance of $260–$290 million with full-year Adjusted EBITDA expected to approach breakeven.
MIMEDX (Nasdaq: MDXG) and Sanara MedTech (Nasdaq: SMTI) signed a definitive merger agreement under which MIMEDX will acquire all outstanding Sanara shares in a cash-and-stock deal valued at $35 per share, implying an enterprise value of about $350 million and a 46% premium to Sanara’s 30-day VWAP.
Sanara holders will receive $33.00 in cash plus 0.4735 MIMEDX shares per Sanara share. MIMEDX plans to fund the cash portion with cash on hand and a new $300 million term loan from Hayfin, replacing its existing credit facility. The companies expect the combination to nearly double MIMEDX’s surgical revenue, push 2027 combined revenue above $400 million with adjusted EBITDA margin over 20%, and generate over $20 million in run-rate cost synergies. The boards of both companies unanimously approved the deal, which is expected to close by year-end, subject to Sanara shareholder and regulatory approvals.
MiMedx (Nasdaq: MDXG) will release its operating and financial results for the second quarter ended June 30, 2026 after market close on Wednesday, July 29, 2026, followed by a webcast and conference call at 4:30 p.m. Eastern Time. U.S. investors can dial 877-407-6184, international investors 201-389-0877, using Conference ID 13761338. A webcast replay will be available for about 30 days on the company’s website.
MIMEDX (Nasdaq: MDXG) announced that senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis, MN.
Interested investors are invited to request meetings with management through their Craig-Hallum representative.
MiMedx (Nasdaq: MDXG) announced the commercial launch of G4Derm Plus on May 8, 2026, with initial U.S. sales already delivered and exclusive U.S. distribution rights secured.
G4Derm Plus is a 510(k)-cleared, acellular flowable extracellular matrix using self-assembling peptide technology. The product supports revascularization, granulation, and re-epithelialization and serves as an antibacterial barrier. The product is available through Premier and Vizient GPO agreements for national hospital access.